Program
SYS6041
A development code. Also written as “SYS6041, bevacizumab”, “SYS6041, carboplatin, bevacizumab” and “SYS6041, enlonstobart, bevacizumab”.
Its studies are mostly in Ovarian Neoplasms, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 22 open or running | phase 2since Jul 8, 2026 | Jul 8, 2026 | Mar 28, 2027phase 2 · NCT07744763 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2026First studies: 2 phase 2 studiesFirst studyNCT07714668, NCT07744763
Ahead
- Mar 28, 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07744763
- Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT07714668
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07744763Advanced Solid Tumors · China | 2 | Recruiting | Mar 28, 2027 | 260 |
| NCT07714668Ovarian Neoplasms · China | 2 | Recruiting | Apr 30, 2028 | 171 |
How it is read
Names in the registry
- “SYS6041, bevacizumab”, 1 entry
- “SYS6041, carboplatin, bevacizumab”, 1 entry
- “SYS6041, enlonstobart, bevacizumab”, 1 entry
- “SYS6041”, 1 entry
Codes read as this program: SYS6041.
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.